Immunic, Inc. (IMUX) stock
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.33+0.10 (+1.38%)
Close on Nov 17, 2026Market cap $100.01MP/E –Yield 0.00%
Immunic total assets
Total assets on the balance sheet at the end of each period.
Immunic's total assets was $159.17M at Jun 30, 2026. For fiscal 2025 it was $24.05M, down 41.1% from the year before. Over ten years it grew -12.3% a year on average. The highest annual figure on record is $167.86M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.05M | -41.1% |
| FY2024 | Dec 31, 2024 | $40.87M | -24.7% |
| FY2023 | Dec 31, 2023 | $54.30M | -57.5% |
| FY2022 | Dec 31, 2022 | $127.75M | -8.2% |
| FY2021 | Dec 31, 2021 | $139.10M | -17.1% |
| FY2020 | Dec 31, 2020 | $167.86M | +154.5% |
| FY2019 | Dec 31, 2019 | $65.96M | +393.3% |
| FY2018 | Dec 31, 2018 | $13.37M | -77.9% |
| FY2017 | Dec 31, 2017 | $60.38M | -5.7% |
| FY2016 | Dec 31, 2016 | $64.03M | -28.1% |
| FY2015 | Dec 31, 2015 | $89.08M | -17.6% |
| FY2014 | Dec 31, 2014 | $108.08M | +132.0% |
| FY2013 | Dec 31, 2013 | $46.59M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $159.17M | +159.1% |
| Q1 FY2026 | Mar 31, 2026 | $189.74M | +824.9% |
| Q4 FY2025 | Dec 31, 2025 | $24.05M | -41.1% |
| Q3 FY2025 | Sep 30, 2025 | $40.70M | -37.1% |
| Q2 FY2025 | Jun 30, 2025 | $61.43M | -29.0% |
| Q1 FY2025 | Mar 31, 2025 | $20.52M | -80.3% |
| Q4 FY2024 | Dec 31, 2024 | $40.87M | -24.7% |
| Q3 FY2024 | Sep 30, 2024 | $64.76M | -3.3% |
| Q2 FY2024 | Jun 30, 2024 | $86.49M | -2.5% |
| Q1 FY2024 | Mar 31, 2024 | $104.16M | -4.3% |
| Q4 FY2023 | Dec 31, 2023 | $54.30M | -57.5% |
| Q3 FY2023 | Sep 30, 2023 | $66.98M | -44.7% |
| Q2 FY2023 | Jun 30, 2023 | $88.74M | -36.0% |
| Q1 FY2023 | Mar 31, 2023 | $108.87M | -27.4% |
| Q4 FY2022 | Dec 31, 2022 | $127.75M | -8.2% |
| Q3 FY2022 | Sep 30, 2022 | $121.08M | -22.8% |
| Q2 FY2022 | Jun 30, 2022 | $138.66M | +1.9% |
| Q1 FY2022 | Mar 31, 2022 | $149.92M | -3.1% |
| Q4 FY2021 | Dec 31, 2021 | $139.10M | -17.1% |
| Q3 FY2021 | Sep 30, 2021 | $156.76M | -8.7% |
| Q2 FY2021 | Jun 30, 2021 | $136.06M | +56.1% |
| Q1 FY2021 | Mar 31, 2021 | $154.72M | +170.1% |
| Q4 FY2020 | Dec 31, 2020 | $167.86M | +154.5% |
| Q3 FY2020 | Sep 30, 2020 | $171.64M | +153.9% |
| Q2 FY2020 | Jun 30, 2020 | $87.15M | +20.1% |
| Q1 FY2020 | Mar 31, 2020 | $57.29M | +446.6% |
| Q4 FY2019 | Dec 31, 2019 | $65.96M | +393.3% |
| Q3 FY2019 | Sep 30, 2019 | $67.60M | +238.2% |
| Q2 FY2019 | Jun 30, 2019 | $72.57M | +108.5% |
| Q1 FY2019 | Mar 31, 2019 | $10.48M | -77.7% |
| Q4 FY2018 | Dec 31, 2018 | $13.37M | -77.9% |
| Q3 FY2018 | Sep 30, 2018 | $19.99M | -71.6% |
| Q2 FY2018 | Jun 30, 2018 | $34.80M | -56.9% |
| Q1 FY2018 | Mar 31, 2018 | $47.01M | -48.3% |
| Q4 FY2017 | Dec 31, 2017 | $60.38M | -5.7% |
| Q3 FY2017 | Sep 30, 2017 | $70.36M | -2.9% |
| Q2 FY2017 | Jun 30, 2017 | $80.68M | – |
| Q1 FY2017 | Mar 31, 2017 | $90.95M | – |
| Q4 FY2016 | Dec 31, 2016 | $64.03M | – |
| Q3 FY2016 | Sep 30, 2016 | $72.47M | – |
See a number that looks wrong?